Compare OLLI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLLI | CRSP |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | 393 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.8B |
| IPO Year | 2015 | 2016 |
| Metric | OLLI | CRSP |
|---|---|---|
| Price | $87.64 | $49.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 23 |
| Target Price | ★ $101.60 | $85.63 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 12-08-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.43 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $2,649,198,000.00 | $289,590,000.00 |
| Revenue This Year | $10.78 | $1,052.09 |
| Revenue Next Year | $11.15 | $273.88 |
| P/E Ratio | $39.68 | ★ N/A |
| Revenue Growth | 16.62 | ★ 9169.85 |
| 52 Week Low | $60.29 | $44.12 |
| 52 Week High | $130.40 | $67.66 |
| Indicator | OLLI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 40.38 |
| Support Level | $71.95 | $45.61 |
| Resistance Level | $89.12 | $60.71 |
| Average True Range (ATR) | 3.23 | 2.51 |
| MACD | -0.34 | -0.23 |
| Stochastic Oscillator | 38.29 | 14.64 |
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name-brand household items that consumers use every day at prices heavily discounted compared with traditional retailers. It offers customers a broad selection of brand-name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. The company operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun, engaging treasure-hunt shopping experience, a compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.